Evotec Valuation Multiples

Evotec Overview

About Evotec

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Founded

1993

HQ

Employees

4.8K

Website

evotec.com

Sectors

Contract Research & ManufacturingBioTech

Financials (LTM)

Revenue: $931M

EBITDA: $52M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Evotec Financials

Evotec reported last 12-month revenue of $931M and EBITDA of $52M.

In the same LTM period, Evotec generated $147M in gross profit, $52M in EBITDA, and had net loss of ($105M).

Evotec P&L

In the most recent fiscal year, Evotec reported revenue of $933M and EBITDA of $52M.

Evotec expects next 12-month revenue of XXX and NTM EBITDA of XXX

Evotec Stock Performance

Evotec has current market cap of $1B, and enterprise value of $1B.

Evotec's stock price is $6.56.

Evotec Valuation Multiples

Evotec trades at 1.2x EV/Revenue multiple, and 22.2x EV/EBITDA.

Evotec Financial Valuation Multiples

As of April 18, 2026, Evotec has market cap of $1B and EV of $1B.

Equity research analysts estimate Evotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Evotec has a P/E ratio of (11.1x).

Evotec Margins & Growth Rates

Evotec's revenue in the last 12 month grew by 3%.

Evotec's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Evotec's rule of 40 is 5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Evotec's rule of X is 5% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Evotec Public Comps

See public comps and valuation multiples for other Contract Research & Manufacturing comps.

Evotec M&A Activity

Evotec acquired XXX companies to date.

Last acquisition by Evotec was on XXXXXXXX, XXXXX. Evotec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Evotec Investment Activity

Evotec invested in XXX companies to date.

Evotec made its latest investment on XXXXXXXX, XXXXX. Evotec invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).